News

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
PMLive4h
Bayer’s Kerendia granted FDA approval for new heart failure indication
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
Medical Dialogues5h
FDA Expands Finerenone Indication to Include Heart Failure
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
Pharmabiz5h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
AHA/ASA Journals19h
The Promise and Peril of Learning Algorithms and Predictive Models in Clinical Decision Support: Be Careful What You Train For
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
Astronomers use simulations to reconstruct three-star ejection from R136 cluster
Astronomers led by Simon Portegies Zwart used simulations to reconstruct how three stars were ejected from the star cluster ...
Daily Jang23h
FDA approves Kerendia for cardiac failure with LVEF ≥40 percent
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...